| | hsCRP | | | Variables | Quartile 1 (<35.1 nmol/L) | Quartile 2 (35.1–69.4 nmol/L) | Quartile 3 (69.4–141.8 nmol/L) | Quartile 4 (>141.8 nmol/dL) | value |
| | Male, (%) | 543 (44.4) | 570 (47.9) | 625 (52.3) | 607 (50.8) | <0.001 | | Age, year | 59.3 ± 10.5 | 59.9 ± 10.5 | 58.7 ± 10.5 | 60.3 ± 11.9 | 0.001 | | BMI, kg/m2 | 24.3 ± 3.0 | 24.6 ± 3.2 | 24.7 ± 3.3 | 24.9 ± 3.7 | 0.059 | | HTN, (%) | 877 (71.7) | 821 (69.0) | 770 (64.4) | 860 (72.0) | 0.535 | | DM, (%) | 460 (37.6) | 622 (52.3) | 799 (66.8) | 756 (63.3) | <0.001 | | Insulin | 103 (8.4) | 160 (13.5) | 243 (20.3) | 276 (23.1) | <0.001 | | Oral medication | 406 (33.2) | 543 (45.7) | 731 (61.1) | 667 (55.9) | <0.001 | | Newly diagnosed | 49 (4.0) | 60 (5.0) | 52 (4.3) | 63 (5.3) | 0.248 | | CKD, (%) | 92 (7.5) | 95 (8.0) | 85 (7.1) | 175 (14.7) | <0.001 | | eGFR, mL/min | 91.7 ± 25.6 | 90.9 ± 26.1 | 94.7 ± 26.7 | 87.9 ± 34.0 | <0.001 | | HF, (%) | 54 (4.4) | 48 (4.0) | 40 (3.3) | 90 (7.5) | 0.002 | | Persistent AF, (%) | 49 (4.0) | 31 (2.6) | 30 (2.5) | 65 (5.4) | 0.086 | | Angina pectoris, (%) | 408 (33.3) | 301 (25.3) | 265 (22.2) | 318 (26.6) | <0.001 | | Chest pain, (%) | 345 (28.2) | 261 (22.0) | 227 (19.0) | 286 (24.0) | 0.004 | | Vasospastic angina, (%) | 63 (5.1%) | 40 (3.4) | 38 (3.2) | 32 (2.7) | 0.001 |
| | Laboratory findings | | TC, mmol/L | 3.96 ± 0.85 | 4.04 ± 0.88 | 3.99 ± 0.91 | 4.07 ± 1.04 | 0.073 | | TG, mmol/L | 1.28 ± 0.70 | 1.51 ± 0.93 | 1.63 ± 1.12 | 1.68 ± 1.06 | <0.001 | | HDL-C, mmol/L | 1.40 ± 0.34 | 1.35 ± 0.34 | 1.30 ± 0.31 | 1.27 ± 0.34 | <0.001 | | LDL-C, mmol/L | 2.25 ± 0.73 | 2.28 ± 0.78 | 2.25 ± 0.80 | 2.33 ± 0.85 | 0.011 | | hsCRP, nmol/L | 2.7 ± 1.0 | 6.7 ± 1.0 | 12.4 ± 2.7 | 86.7 ± 173.3 | <0.001 | | Fasting glucose, mmol/L | 6.27 ± 1.78 | 6.66 ± 1.94 | 7.10 ± 2.28 | 7.05 ± 2.72 | <0.001 | | HbA1c, % | 6.5 ± 1.1 | 6.7 ± 1.1 | 6.9 ± 1.3 | 7.0 ± 1.4 | <0.001 | | Cr, μmol/L | 68.6 ± 76.3 | 68.6 ± 68.6 | 76.3 ± 83.9 | 91.5 ± 114.4 | <0.001 | | Lp (a), μmmol/L | 1.04 ± 1.18 | 0.93 ± 0.89 | 0.96 ± 1.07 | 1.11 ± 1.21 | 0.248 | | Apo A-I, g/L | 1.46 ± 0.23 | 1.44 ± 0.25 | 1.40 ± 0.26 | 1.39 ± 0.28 | 0.013 | | Apo B, g/L | 0.67 ± 0.20 | 0.67 ± 0.20 | 0.70 ± 0.21 | 0.73 ± 0.23 | 0.002 | | Apo C-II, g/L | 0.04 ± 0.02 | 0.04 ± 0.02 | 0.04 ± 0.02 | 0.04 ± 0.02 | 0.275 | | Apo E, g/L | 0.03 ± 0.01 | 0.03 ± 0.01 | 0.03 ± 0.01 | 0.03 ± 0.01 | 0.016 |
| | Type of statins | | | | | 0.009 | | Atorvastatin, (%) | 628 (51.3) | 573 (48.2) | 644 (53.8) | 558 (46.7) | | | Simvastatin, (%) | 264 (21.6) | 265 (22.3) | 229 (19.1) | 253 (21.2) | | | Rosuvastatin, (%) | 162 (13.2) | 187 (15.7) | 178 (14.9) | 227 (19) | | | Pitavastatin, (%) | 91 (7.4) | 81 (6.8) | 77 (6.4) | 72 (6.0) | | | Pravastatin, (%) | 48 (3.9) | 50 (4.2) | 33 (2.8) | 46 (3.9) | | | Fluvastatin, (%) | 31 (2.5) | 33 (2.8) | 35 (2.9) | 38 (3.2) | | | Follow-up, days | 1,817 ± 736 | 1,865 ± 788 | 1,605 ± 760 | 1,709 ± 791 | <0.001 |
|
|
LDL-C, low-density lipoprotein cholesterol; BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HF, heart failure; AF, atrial fibrillation; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; HbA1c, glycated hemoglobin; Cr, creatinine; Lp, lipoprotein; Apo, apolipoprotein.
|
